|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM180845144 |
003 |
DE-627 |
005 |
20231223160206.0 |
007 |
cr uuu---uuuuu |
008 |
231223s2008 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.1016/j.clim.2008.02.013
|2 doi
|
028 |
5 |
2 |
|a pubmed24n0603.xml
|
035 |
|
|
|a (DE-627)NLM180845144
|
035 |
|
|
|a (NLM)18620909
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Sánchez-Ramón, Silvia
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Memory B cells in common variable immunodeficiency
|b clinical associations and sex differences
|
264 |
|
1 |
|c 2008
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 05.09.2008
|
500 |
|
|
|a Date Revised 23.02.2022
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a Common variable immunodeficiency (CVID) is a heterogeneous syndrome characterized by impaired antibody responses, recurrent infections, inflammatory, autoimmune and malignancy-related conditions. We evaluated the relationship between memory B cell phenotype, sex, age at diagnosis, immunologic and clinical conditions in 105 CVID subjects from one medical center. Reduced numbers of switched memory B cells (cutoff <or=0.55% of B cells) were an independent risk factor of granulomas, autoimmune diseases and splenomegaly (p<0.001). Not previously noted, CVID females had significantly more switched memory cells (p=0.007) than males. Splenectomized subjects did not have fewer IgM memory B cells and these numbers were not related to the development of lung disease, as previously proposed. Lower baseline serum IgG was an independent predictor of pneumonia (p=0.007) and severe infections (p=0.001). We conclude that outcomes in CVID depend on an interplay of factors including sex, numbers of switched memory B cells, and baseline serum IgG and IgA levels
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
650 |
|
7 |
|a Antibodies
|2 NLM
|
650 |
|
7 |
|a Immunoglobulin A
|2 NLM
|
650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
650 |
|
7 |
|a Pneumococcal Vaccines
|2 NLM
|
700 |
1 |
|
|a Radigan, Lin
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Yu, Joyce E
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Bard, Susan
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Cunningham-Rundles, Charlotte
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 128(2008), 3 vom: 01. Sept., Seite 314-21
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
773 |
1 |
8 |
|g volume:128
|g year:2008
|g number:3
|g day:01
|g month:09
|g pages:314-21
|
856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2008.02.013
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 128
|j 2008
|e 3
|b 01
|c 09
|h 314-21
|